NewEdge Advisors LLC Sells 24,550 Shares of Pfizer Inc. $PFE

NewEdge Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the second quarter, Holdings Channel.com reports. The institutional investor owned 687,769 shares of the biopharmaceutical company’s stock after selling 24,550 shares during the quarter. NewEdge Advisors LLC’s holdings in Pfizer were worth $16,561,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Keb Asset Management LLC bought a new stake in Pfizer in the second quarter valued at approximately $26,000. Field & Main Bank acquired a new stake in Pfizer in the second quarter worth $27,000. HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. boosted its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Stock Performance

PFE opened at $27.63 on Friday. The company has a market capitalization of $157.50 billion, a price-to-earnings ratio of 36.36, a P/E/G ratio of 1.87 and a beta of 0.34. The business’s 50-day moving average price is $26.28 and its two-hundred day moving average price is $26.36. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $29.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s dividend payout ratio is 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.